US Bio Company CEO and CFO Realize Billions in Gains by Selling Shares

United Therapeutics Corporation (NASDAQ: UTHR) disclosed that on March 20 and 23, 2026, founder and CEO Martine A. Rothblatt and CFO James Edgemond each exercised stock options and sold common shares in the open market. Rothblatt sold shares at approximately $520–530 per share over multiple transactions, netting roughly $5.0 million (about ₩7 billion) and reducing her direct holdings from about 50,000 to 40,513 shares. Edgemond similarly sold option shares in the $520–530 range on the same days, realizing approximately $5.2–5.3 million (about ₩7 billion) and cutting his direct stake from 28,876 to 18,876 shares. Both executives traded under pre-arranged Rule 10b5-1 trading plans established at the end of 2025.

On April 16, 2026, Executive Vice President and General Counsel Mahon sold 8,300 common shares, raising about $4.78 million (roughly ₩6 billion). In March, the company also approved a new share-repurchase program of up to $2 billion (approximately ₩2.7 trillion), further expanding its shareholder-return policy.

United Therapeutics is a biotechnology firm headquartered in Maryland and North Carolina that focuses on treatments for rare pulmonary diseases, including pulmonary arterial hypertension, as well as the development of artificial organs for transplantation and xenotransplantation technologies. Founded in 1996 and led by Rothblatt since inception, the company reported 2023 revenues of about $2.3 billion (around ₩3 trillion).